Alkyn-containing nucleotides and nucleoside therapeutic compositions and related uses thereof

By developing alkyne-modified nucleotide and nucleoside compositions, the problems of low permeability and activation efficiency of antiviral agents have been solved, enabling effective treatment of various viruses and cancers and providing multiple drug composition forms.

CN122127383APending Publication Date: 2026-06-02EMORY UNIVERSITY
View PDF 482 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
EMORY UNIVERSITY
Filing Date
2017-04-28
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Existing antiviral agents have difficulty penetrating the virus-protected zone, resulting in incomplete clearance of HIV infection and the development of resistance. Furthermore, the activation of nucleoside analogs within the host is limited.

Method used

Develop therapeutic compositions of nucleotides and nucleosides containing alkynes, which are conjugated with nucleotides or nucleosides via phosphorus oxides or their salts to form conjugated compounds or their salts, containing amino acid esters, lipids or sphingolipid derivatives, targeting viral RNA-dependent RNA polymerases to enhance antiviral efficacy.

Benefits of technology

It improves the permeability and activation efficiency of antiviral agents, enabling effective treatment of various viral infections and cancers, including HIV and hepatitis B. It also provides multiple drug combination forms, enhancing the inhibitory effect on viruses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_24
    Figure SMS_24
  • Figure SMS_47
    Figure SMS_47
Patent Text Reader

Abstract

This disclosure relates to nucleotide and nucleoside therapeutic compositions and their use in treating infectious diseases, viral infections and cancer, wherein the bases of said nucleotide or nucleoside contain at least one thiol, thion, or thioether.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Nucleotide phosphoramidates as anticancer agents

    CA2518115C

  • Pharmaceutical active substance for the treatment of hepatitis A, hepatitis C, borrelia and / or multiple sclerosis, comprises an unpurified gland secretion obtained from animals of the class Diplopoda

    DE102005038768A1

  • Pharmaceutical compositions comprising metal oxides and uses thereof

    EP1627641A1

  • Nucleotide phosphoramidates as anticancer agents

    EP1646639A2

  • Methods for reducing the side effects associated with mirtazapine treatment

    EP1827450A2